New attack on tough lymphoma: second CAR-T therapy tested after first fails
NCT ID NCT04316624
Summary
This early-stage study tested a new type of CAR-T cell therapy called C-CAR066 in a small group of patients with an aggressive form of lymphoma (DLBCL) whose cancer had come back after they had already received a different CAR-T treatment. The main goals were to check if the treatment was safe and to see if it could help control the cancer. Patients received a single infusion of these specially engineered immune cells after undergoing chemotherapy to prepare their body.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Institute of Hematology & Blood Diseases Hospital
Tianjin, 300020, China
Conditions
Explore the condition pages connected to this study.